ZIM Laboratories Ltd

Zim Laboratories Ltd announced that CARE Ratings Limited has reaffirmed the ratings for the company's bank facilities, specifically Long-term bank facilities amounting to Rs 127.48 crores, now rated CARE BBB with a Negative outlook (previously Stable), and Short-term bank facilities amounting to Rs 12.00 crores, reaffirmed at CARE A3; no other rating agencies were mentioned and there were no enhancements, assignments, or withdrawals related to these instruments.

Zim Laboratories Limited informed the Bombay Stock Exchange and National Stock Exchange that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, confirmed compliance under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Zim Laboratories Limited informed the BSE Limited and National Stock Exchange of India Limited that it will close the trading window for dealing with securities of the company for designated persons and their immediate relatives from October 1, 2026, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s code of conduct, reopening 48 hours after the declaration of financial results for the quarter ended September 30, 2026.

ZIM LABORATORIES LIMITED announced the incorporation of its wholly owned subsidiary, ZIM Laboratories SpA, in Santiago, Republic of Chile, on September 9, 2026. The subsidiary, incorporated with a cash consideration, will focus on expanding and developing the company’s pharmaceutical business in the Latin America (LATAM) region, with ZIM Laboratories Limited subscribing to 14,100 shares at a face value of Chilean Pesos 1,000 each, resulting in 100% shareholding.

ZIM Laboratories Limited announced that its wholly-owned subsidiary, ZIM Laboratories Limited FZE, has completed an investment of AED 4,66,000 and AED 4,50,000 in ZIM Scientific Office LLC, a step-down subsidiary, as previously disclosed on March 28, 2025, and August 7, 2025, maintaining ZIM FZE’s 100% shareholding in ZIM SO.

Zim Laboratories Ltd share price inched up 4.47% to Rs 114.55. The Company's net profit witnessed a sharp fall of 207.49% to Rs 4.02 crore, while revenue from operations slipped 10.53% to Rs 94.18 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, gaining 5.02%. It has improved by 1.03% over last one week and rose by 11.63% in last one month while the market capitalization of Zim Laboratories Ltd has slipped by 0.39% and 11.44% in the same period respectively. Profit before tax (PBT) of Zim Laboratories Ltd stood at Rs 5.57 crore in Q2 FY26, jumping 129.22% year-on-year, and crashing by 212.75% quarter-on-quarter. EBITDA came in at Rs 1 crore, nosediving by 47.48% YoY and surging by 41.75% sequentially. Total expenses marginally dropped 5.89% to Rs 97.1 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 43.82 crore, falling by 11.83% YoY, while employee benefits expense was at Rs 19.18 crore, expanding by 10.29% YoY. For the TTM ended FY26, revenue from operations declined slightly by 1.22% to Rs 374.4 crore, while net profit plunged by 52.01% to Rs 5.84 crore, compared to previous TTM. EBITDA jumped by 3681% to Rs 18.63 crore, and PBT tanked by 54.41% to Rs 8.21 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 49.53 crore in FY26, as against Rs 41.15 crore in FY25. Zim Laboratories Ltd soared by 42.74% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.

ZIM LABORATORIES LIMITED will hold a board meeting on Thursday, August 6, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, according to a filing with the BSE Limited and National Stock Exchange of India Limited. The trading window for the company's securities will be closed from Wednesday, July 1, 2026, to Saturday, August 8, 2026, in accordance with SEBI regulations and the company’s code of conduct.

Zim Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 29 June 2026.

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 19 May 2026.

Net profit of Zim Laboratories rose 10.00% to Rs 4.40 crore in the quarter ended December 2025 as against Rs 4.00 crore during the previous quarter ended December 2024. Sales rose 12.80% to Rs 108.66 crore in the quarter ended December 2025 as against Rs 96.33 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales108.6696.33 13 OPM %11.7912.01 - PBDT11.0810.58 5 PBT6.055.70 6 NP4.404.00 10 Powered by Capital Market - Live